KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinomaNikolaj Frost, Christian Grohé, Elisabeth Olive et al.|Translational Lung Cancer Research|2021Cited by 60
Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer – A multicenter observational analysisNikolaj Frost, Jens Kollmeier, Kristina Unger et al.|Lung Cancer|2023Cited by 18
Prävention, Diagnostik, Therapie und Nachsorge des LungenkarzinomsWolfgang Schütte, Dag Wormanns, S Gütz et al.|Pneumologie|2023Cited by 9
Efficacy and safety of nivolumab in routine NSCLC treatment – an observational study in 5 lung cancer centers in Berlin, GermanyDaniel Misch, Annette Reinecke, Maike de Wit et al.|Lung Cancer|2017Cited by 2